Calls

Description :

HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to all the following expected outcomes:

• Healthcare providers, researchers and patients get faster access to innovative therapies.
• The European Union benefits from more clinical trials being conducted with new biotech therapeutic approaches.
• The competitiveness of small and medium-sized enterprises (SMEs) from the EU and Associated Countries within the health biotech sector is strengthened.

More info

Description :

HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to all the following expected outcomes:

• Researchers, including clinical researchers, have access to robust, trustworthy and ethical Generative Artificial Intelligence (AI)[1] models able to effectively advance biomedical research towards predictive and personalised medicine.
• Researchers, including clinical researchers, know how to use Generative AI models to synthesise the available scientific information and large-scale multimodal data and how to apply the necessary precautions, in order to deliver new knowledge and breakthrough scientific discoveries.
• Research community benefits from advanced methodologies to assess the validity and application of accurate, transparent, traceable, and explainable Generative AI models.

More info

Description :

HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to several of the following expected outcomes:

• Researchers and biopharmaceutical developers work together with clinicians striving to translate innovative therapeutic approaches into healthcare solutions.
• Producers of innovative health technologies use standardised manufacturing processes.
• Healthcare providers get access to a new type of innovative therapies with demonstrated health benefits as compared to traditional treatments.
• Patients benefit from innovative therapies for conditions for which there are currently no or only insufficient therapeutic strategies.
• Health systems ultimately benefit from improved patient outcomes, superior to the current standard of care.

More info

Description :

HORIZON-HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to several of the following expected outcomes:

• Biomedical scientists dispose of tools that allow them to engineer cells with specific therapeutic features.
• Improved methods and assays are available for biopharmaceutical developers.
• Clinicians will get access to innovative therapeutic approaches enabling them to treat conditions, where there are currently no or only insufficient therapeutic strategies.
• Cell engineering will be enriched and pave the way for novel personalised therapy options.

More info

Description :

HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to all the following expected outcomes:

• Healthcare professionals, at all stages of healthcare provision, have access to user-centric, robust and trustworthy virtual assistant solutions based on Generative Artificial Intelligence (AI)^[1] models and other AI tools to support them towards the provision of safer, more efficient and personalised care.
• Healthcare professionals benefit from cross-country applicable methodologies with the aim to facilitate acceptability, healthcare uptake and public trust of virtual assistant tools based on Generative AI models.
• Patients benefit from enhanced outcomes, more personalised care, and increased engagement with their healthcare professionals, leading to improved safety, quality of care, access to appropriate healthcare information and patient-doctor communication.
• Healthcare systems benefit from improved cost-effective patient outcomes, superior to standard of care in terms of accuracy, safety, and quality, and from cost-savings through advancements in highly accurate, transparent, traceable, and explainable solutions.

More info

Description :

HORIZON-HLTH-2025-01-DISEASE-07: Tackling high-burden for patients and under-researched medical conditions

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to most of the following expected outcomes:

• The scientific and clinical communities make effective use of state-of-the-art information, data, technologies, tools and best practices to better understand the condition, underpinning the development of diagnostics, therapeutics and/or preventive strategies.
• The scientific and clinical community exchange data, knowledge and best practices, thereby strengthening their collaboration and building knowledge and care networks in Europe and beyond.
• The scientific and clinical community make wide use of newly established and where relevant open access databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR^[1] principles, thereby encouraging further use of the data.
• Policymakers and funders are informed of the research advances made and consider further support in light of the sustainability of the studies.
• Patients and caregivers are constructively engaged with the research, which also caters for their needs.
• Health professionals have access to and use improved clinical guidelines on diagnosis and/or treatment of the condition.

More info

Description :

HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to some of the following expected outcomes:

• Healthcare practitioners and providers in low- and middle-income countries (LMICs)[1] and/or those in high-income countries (HICs) serving disadvantaged populations have access to information allowing to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (NCDs).
• Public health managers and authorities have access to improved insights and evidence on how to decrease the fragmentation of care for patients living with NCDs and ensure continuity of care across all stages of disease progression, including prevention, risk reduction, and timely diagnosis of NCDs. They use this knowledge to design policies to reduce health inequities and to promote equitable health outcomes.
• Researchers, clinicians and authorities have an improved understanding how the proposed interventions for strengthening health systems for equitable high-quality care and health outcomes in the context of NCDs could be adopted in LMICs and/or disadvantaged populations of HICs setting, taking into account specific social, political, economic and cultural contexts.
• Communities, local stakeholders and authorities are fully engaged in implementing and taking up interventions that strengthen health systems for equitable high-quality care and health outcomes in the context of NCDs and thus contribute to deliver better health, improve quality of life across the life course and extend healthy life expectancy.

Full details

Description :

HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all the following expected outcomes:

• The potential of Artificial Intelligence (AI) is used in all aspects that determine optimal pandemic preparedness and response, and fast learning systems are supported, to the benefit of scientists, public health responders and policymakers. This includes using the full potential of available quality data for research and innovation to transform the development of medical, social or logistical countermeasures, as well as the detection, management and monitoring of emergencies at population levels, and the diagnosis, treatment, and prevention at the level of individuals.
• European pandemic preparedness and response benefits from readily available, trustworthy and ethical AI-based tools and technologies that enable it to act fast and in a targeted manner, to timely detect and understand emerging infectious threats, to respond adequately and proportionally to identified threats, and to control such threats effectively and efficiently.
• Different data types from multiple sources and disciplines across the EU and globally can be accessed, integrated and analysed by scientists, public health responders and policymakers, using trustworthy and ethical AI-based tools and technologies that support pandemic preparedness and response.

Full details

Description :

Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all the following expected outcomes:

• The scientific and clinical communities have a better understanding of prophylactic and treatment options complementary to low molecular weight antiviral therapeutics for viruses with epidemic potential.
• The scientific and clinical communities have access to experimental antibodies and antibody-derived proteins for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.
• Candidate antiviral therapies, including potentially those of broad spectrum are available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.

Full details

Description :

Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to most of the following expected outcomes:

• Researchers and developers make the best use of the state-of-the-art knowledge and resources for an effective development of new treatment options for patients suffering from difficult-to-treat infections.
• Healthcare professionals and people living with difficult-to-treat infections are ultimately provided with the availability of clinically useful phage therapies.
• Regulators are provided with quantifiable, verifiable and replicable data on safety and efficacy of phage therapy for human use and move faster towards market approval of novel phage-based therapies against antimicrobial resistant infections.
• Citizens are engaged and informed on innovative phage-based treatments as alternative therapeutic options complementary to antibiotics.

Full details

Description :

Advancing knowledge on the impacts of micro- and nanoplastics on human health

Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Living and working in a health-promoting environment”. To that end, proposals under this topic should aim to deliver results that are directed, tailored and contributing to most of the following expected outcomes:

• Environmental and health policies reducing exposure to micro- and nanoplastics and preventing their potential health impacts are supported with up-to-date scientific evidence, standards, tools and methodologies;
  Public authorities and the scientific community have access to FAIR[1] data on realistic human exposures to micro- and nanoplastics and their potential impacts on human health based on real-world scenarios across living and working environments;
• Citizens are informed about the impacts of exposure to micro- and nanoplastics on health and adopt behaviours protecting health and reducing human impacts on the environment;
  Industry is supported in the assessment of products’ safety and sustainability;
• Existing major knowledge gaps in the understanding of the health impacts of exposure to micro- and nanoplastics are filled and mitigation measures based on robust evidence are promoted;
• Public authorities and regulators are supported with evidence-based guidance to design health policies.

Full details

Description :

Improving the quality of life of persons with intellectual disabilities and their families

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Living and working in a health-promoting environment”. To that end, proposals under this topic should aim to deliver results that are directed, tailored and contributing to most of the following expected outcomes:

• Global and EU policies preventing and reducing the health impacts of pollution are supported with up-to-date scientific evidence, tools and methodologies;
• Citizens are more protected by having a better insight into exposure to pollution and its impacts on brain health and adopting health enhancing behaviours;
• Public authorities, health stakeholders, the scientific community and the society at large have access to FAIR^[1] data on the link between pollution and brain health, particular windows of susceptibility to exposure and the impacts of pollution on the general population and vulnerable groups;
• Public authorities develop adequate evidence-based measures and guidelines to prevent and reduce the negative impacts of pollution in the development of brain disease.

Full details

Description :

The impact of pollution on the development and progression of brain diseases and disorders

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Staying healthy in a rapidly changing society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to several of the following expected outcomes:

• Persons with intellectual disabilities and their families enjoy an improved quality of life, are empowered and have more independence through the support of innovative research.
• The scientific community develops innovative solutions - medical, technological, digital or others - to reverse and/or reduce the severity level of the intellectual disability as soon as possible, especially in children, improving the health and autonomy of persons with intellectual disabilities and relieving their carers.
• Policymakers, health and care services, patient organisations, funders, the scientific community, and other relevant bodies are informed of the research advances and best practices addressing the health and needs of persons with intellectual disabilities and help reduce the impact of those disabilities on individuals, their families and society.

Full details

Description :

IHI call 10 - a standard, two-stage call

IHI call 10 will be a standard, two-stage call for proposals with the following topics

• Digital label: one source of comprehensive information for medical technology products
• Enabling and safeguarding innovation in secondary use of health data in the European Health Data Space (EHDS)
• Per- and Poly-fluoroalkyl substance (PFAS) exposure, emissions, and end of life management in the healthcare sector

Read the full call text:

Here

Description :

IHI call 9 – a single-stage, applicant driven call

IHI call 9 will be a single-stage, applicant-driven call with five topics aligned with the five specific objectives set out in the IHI Strategic Research and Innovation Agenda (SRIA). For this call, the IHI want applicants to explore the SRIA and identify untapped opportunities that could be transformed into public-private projects through IHI.

Proposals will still have to adhere to the philosophy of IHI. In other words, they will have to: address an unmet public health need; require a large-scale, ambitious, cross-sector, public-private partnership; have clearly-described impacts on society, the economy and science; take account of the pre-competitive nature of IHI projects.

The call will open in early 2025, date TBD. 

Answers to FAQs can be found here.

Description :

The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) in priority areas addressing European Public Health Needs.

This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming. Under this umbrella, ERA4Health is glad to pre-announce the launch of a first Joint Transnational Call (JTC) in multi-country Investigator-Initiated Clinical Studies (IICS) on “Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases” (EffecTrial).

The aims of the call are:

• To support randomised, interventional and pragmatic comparative-effectiveness multi-country Investigator-Initiated Clinical Studies (IICS).
• To encourage and enable transnational collaboration between clinical/public health research teams (from hospital/ public health, healthcare settings and other healthcare organisations) that conduct comparative-effectiveness multi-country IICS.

The project duration is 48 months and it is co-funded by Horizon Europe.

📅 Upcoming Info Day: 27 November from 14h30–16h30 CET (details coming soon).

More information available here

Description :

The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.

ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.

The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.

ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.